BackDrugs Made In America Acquisition Rights Overview

Drugs Made In America Acquisition Rights Current Assets

Track Drugs Made In America Acquisition Rights's current assets ($69K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$69184.00
↑ 39.13% YoYΔ $19458.00 vs prior year quarter

Peer trimmed avg / median

Loading

Drugs Made In America Acquisition Rights Current Assets History

Loading

Drugs Made In America Acquisition Rights vs. peers: Current Assets Comparison

Loading

Drugs Made In America Acquisition Rights Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Drugs Made In America Acquisition Rights (DMAAR) FAQ

As of the most recent data (June 2026), DMAAR shows a current assets of $69K. That compares with $50K in the prior-year period — up 39.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DMAAR's current assets is now $69K (was $50K) — a 39.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Drugs Made In America Acquisition Rights is outperforming or lagging.

Tracking DMAAR's current assets over time shows whether Drugs Made In America Acquisition Rights is scaling, shrinking, or reshaping that part of the business. The current reading is $69K That compares with $50K in the prior-year period — up 39.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Drugs Made In America Acquisition Rights's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $69K) with ownership activity and broader fundamentals.